The IFN-γ pathway is activated when IFN-γ receptor 1/2 (IFNγR1/2) on tumor cells are recognized by IFN-γ, activating the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway, then inducing the expression of PD-L1 to inhibit the ICI therapy (60). The gene discussed is CD274; the disease is neoplasm.